{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-346859","form_type":"8-K","ticker":"ACRV","cik":"0001781174","company_name":"Acrivon Therapeutics, Inc.","filed_at":"2026-08-12T20:10:20+00:00","discovered_at":"2026-08-12T20:12:29.393155+00:00","generated_at":"2026-08-12T20:12:46.763811+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Acrivon Q2 2026 net loss $18.0M; cash $90.0M funds into Q4 2027","bullets":["Net loss $18.0M vs $21.0M in Q2 2025; R&D expense $13.8M vs $16.2M prior year.","Cash, equivalents and investments $90.0M as of Jun 30, 2026, expected to fund ops into Q4 2027.","ACR-368 Phase 2b prespecified interim analysis in serous EC on track for H2 2026; Phase 3 initiation planned H1 2027.","ACR-2316 entered randomized dose expansion at 120mg and 160mg oral QD in AP3-prioritized tumor types.","IND filing for CDK11 inhibitor candidate planned H1 2027; additional AP3 programs to start in 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-346859","json":"https://secwatch.observer/filing/0001193125-26-346859.json","markdown":"https://secwatch.observer/filing/0001193125-26-346859.md","text":"https://secwatch.observer/filing/0001193125-26-346859.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1781174/000119312526346859/0001193125-26-346859-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1781174/000119312526346859/acrv-20260812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-12T20:12:46.763811+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}